Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04816916
Recruitment Status : Recruiting
First Posted : March 25, 2021
Last Update Posted : January 13, 2022
Information provided by (Responsible Party):
Axcella Health, Inc

Brief Summary:
This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.

Condition or disease Intervention/treatment Phase
Hepatic Encephalopathy Drug: AXA1665 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Actual Study Start Date : June 29, 2021
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: AXA1665 53.8 g per day
AXA1665 administered orally TID
Drug: AXA1665
AXA1665 administered TID with food

Placebo Comparator: Matching placebo
Placebo administered orally TID
Drug: Placebo
Matching placebo administered TID with food

Primary Outcome Measures :
  1. Change in neurocognitive function by Psychometric Hepatic Encephalopathy Score (PHES) [ Time Frame: Baseline to week 24 ]

Secondary Outcome Measures :
  1. Time to and frequency of recurrent overt hepatic encephalopathy [ Time Frame: Baseline to week 24 ]
  2. Impact on physical function assessed by Liver Frailty Index (a composite measure of hand grip strength, balance and ability to stand up from a chair) [ Time Frame: Baseline to week 24 ]
  3. Incidence of study product emergent adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Baseline to week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing to participate in the study and provide written informed consent.
  • Male and female adults aged > 18 years.
  • History of cirrhosis and at least 1 documented prior episode of overt hepatic encephalopathy within 24 weeks prior to Screening;
  • A PHES ≤ -4 during Screening
  • MELD-Na score of <20 at Screening
  • Support of a primary caregiver who is able and willing to give written informed consent.

Exclusion Criteria:

  • Hospitalization or serious medical condition
  • History or presence of Child's Pugh class C, hepato-renal syndrome(s), refractory ascites or spontaneous bacterial peritonitis (SBP)
  • History of a portosystemic or a transjugular intrahepatic portosystemic shunt (TIPS) placement;
  • Expectation of a liver transplant during the study
  • Screening Alcohol Use Disorders Identification Test (AUDIT) score ≥8

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04816916

Layout table for location contacts
Contact: Margaret Koziel, M.D. 1-857-320-2200

Show Show 21 study locations
Sponsors and Collaborators
Axcella Health, Inc
Layout table for investigator information
Principal Investigator: Andres Duarte-Rojo, M.D. University of Pittsburgh
Layout table for additonal information
Responsible Party: Axcella Health, Inc Identifier: NCT04816916    
Other Study ID Numbers: AXA1665-101
First Posted: March 25, 2021    Key Record Dates
Last Update Posted: January 13, 2022
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Axcella Health, Inc:
liver cirrhosis
end stage liver disease
amino acids
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatic Encephalopathy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Liver Diseases
Digestive System Diseases
Liver Failure
Hepatic Insufficiency
Brain Diseases, Metabolic
Metabolic Diseases